Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer

Kodaz, Hilmi

doi:10.14744/ejmo.2017.22931

Cited by 35 publications

(39 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study further confirmed that Asians who harbor NSCLC have similar genetic components ( 16 – 19 ), as also demonstrated in a study conducted among Korean patients ( 14 ). In France, 66% of V600E mutations were observed among BRAF mutated patients ( 20 ).…”

Section: Discussionsupporting

confidence: 90%

Catalog of Lung Cancer Gene Mutations Among Chinese Patients

Xue

Asuquo

Hong³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Detailed catalog of lung cancer-associated gene mutations provides valuable information for lung cancer diagnosis and treatment. In China, there has never been a wide-ranging study cataloging lung cancer-associated gene mutations. This study aims to reveal a comprehensive catalog of lung cancer gene mutations in china, focusing on EGFR, ALK, KRAS, HER2, PIK3CA, MET, BRAF, HRAS, and CTNNB1 as major targets. Additionally, we also aim to correlate smoking history, gender, and age distribution and pathological types with various types of gene mutations. Patients and Methods: A retrospective data acquisition was conducted spanning 6 years (2013–2018) among all patients who underwent lung cancer surgeries not bronchial or percutaneous lung biopsy at three major tertiary hospitals. Finally, we identified 1,729 patients who matched our inclusion criteria. Results: 1081 patients (62.49%) harbored EGFR mutation. ALK ( n = 42, 2.43%), KRAS ( n = 201, 11.62%), CTNNB1 ( n = 28, 1.62%), BRAF ( n = 31, 1.79%), PIK3CA ( n = 51, 2.95%), MET ( n = 14, 0.81%), HER2 ( n = 47, 2.72%), HRAS ( n = 3, 0.17%), and other genes( n = 232, 13.4%). Females expressed 55.38% vs. males 44.62% mutations. Among subjects with known smoking histories, 32.82% smokers, 67.15% non-smokers were observed. Generally, 51.80% patients were above 60 years vs. 48.20% in younger patients. Pathological types found includes LUADs 71.11%, SQCCs 1.68%, ASC 0.75%, LCC 0.58%, SCC 0.35%, ACC 0.17%, and SC 0.06%, unclear 25.19%. Conclusion: We offer a detailed catalog of the distribution of lung cancer mutations. Showing how gender, smoking history, age, and pathological types are significantly related to the prevalence of lung cancer in China.

show abstract

Section: Discussionsupporting

confidence: 90%

Catalog of Lung Cancer Gene Mutations Among Chinese Patients

Xue

Asuquo

Hong³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The only result from StringDB based graphs for possible protein complexes within glioblastoma multiforme listed HER2 and several RAS proto-oncogenes. HER2 gene amplification has been shown in glioblastoma multiforme in correlation to KRAS and NRAS mutations [79,80].…”

Section: Discussionmentioning

confidence: 99%

Open Data for Differential Network Analysis in Glioma

Jean-Quartier¹,

Jeanquartier²,

Holzinger³

2020

IJMS

View full text Add to dashboard Cite

The complexity of cancer diseases demands bioinformatic techniques and translational research based on big data and personalized medicine. Open data enables researchers to accelerate cancer studies, save resources and foster collaboration. Several tools and programming approaches are available for analyzing data, including annotation, clustering, comparison and extrapolation, merging, enrichment, functional association and statistics. We exploit openly available data via cancer gene expression analysis, we apply refinement as well as enrichment analysis via gene ontology and conclude with graph-based visualization of involved protein interaction networks as a basis for signaling. The different databases allowed for the construction of huge networks or specified ones consisting of high-confidence interactions only. Several genes associated to glioma were isolated via a network analysis from top hub nodes as well as from an outlier analysis. The latter approach highlights a mitogen-activated protein kinase next to a member of histondeacetylases and a protein phosphatase as genes uncommonly associated with glioma. Cluster analysis from top hub nodes lists several identified glioma-associated gene products to function within protein complexes, including epidermal growth factors as well as cell cycle proteins or RAS proto-oncogenes. By using selected exemplary tools and open-access resources for cancer research and differential network analysis, we highlight disturbed signaling components in brain cancer subtypes of glioma.

show abstract

“…In this context, NRAS, a member of the RAS family, is found to be mutated in 1-7% of colorectal cancer [23]. In fact, recent researches showcased that mutations in KRAS exons 3 and 4 and NRAS gene exons 2, 3 and 4 are associated with resistance to anti-EGFR antibody or poor prognosis in mCRC [24,25].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer

et al. 2021

View full text Add to dashboard Cite

Background/aim: Colorectal cancer (CRC) is a major public health problem worldwide and in Tunisia due to its increasing incidence. KRAS and NRAS mutations have become a pivotal part of CRC diagnosis, given their association to treatment resistance with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies. We aim to screen for mutations in KRAS and NRAS genes in Tunisian patients with CRC and to explore their correlations with clinicopathological features. Materials and methods: AmoyDx KRAS and NRAS mutation real-time PCR kits were used to screen for mutations in KRAS (exon 2) and NRAS (exons 2, 3 and 4) in 96 CRC tumors. Results: KRAS exon 2 mutations were found in 41.7% (40/96) of the patients. Codon 12 most abundant mutations were G12D and G12V followed by G12A, while G13D is the predominant mutation in codon 13. KRAS exon 2 mutations were associated with older patients (p = 0.029), left-sided tumors (p = 0.037) and greater differentiation (p = 0.044). The prevalence rate of NRAS mutations was 7.3%, mostly in exon 2. These mutations were associated with early stages (p = 0.039) and the absence of lymph node metastasis (p = 0.045). Conclusion: It can be inferred from this study that Tunisian CRC patients have a similar frequency of KRAS and NRAS mutations compared to those observed in other populations. Consequently, screening for KRAS and NRAS mutation is crucial to orientate the therapies and the selection of an appropriate candidate, avoiding patients' unnecessary toxicity and costs.

show abstract

Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer

Cited by 35 publications

References 33 publications

Catalog of Lung Cancer Gene Mutations Among Chinese Patients

Catalog of Lung Cancer Gene Mutations Among Chinese Patients

Open Data for Differential Network Analysis in Glioma

Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer

Contact Info

Product

Resources

About